About this item:

44 Views | 21 Downloads

Author Notes:

Correspondence: Merin Kuruvilla

Disclosures: None.


Research Funding:



  • Science & Technology
  • Life Sciences & Biomedicine
  • Allergy
  • Immunology
  • Eosinophils

Association of antieosinophil therapy with decreased body mass index in patients with severe asthma A preliminary retrospective analysis


Journal Title:

Annals of Allergy, Asthma & Immunology


Volume 122, Number 6


, Pages 649-650

Type of Work:

Article | Post-print: After Peer Review


The type 2 high endotype of asthma with adult onset is often characterized by severe, persistent, steroid-refractory eosinophilic inflammation. Interleukin 5 (IL-5) is a pivotal cytokine for eosinophil survival. The amelioration of eosinophilic inflammation through anti—IL-5 therapies (mepolizumab, reslizumab, and ben-ralizumab) reduces exacerbations and improves control is and well tolerated overall.

Copyright information:

© 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Export to EndNote